

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Faricimab for treating diabetic macular oedema ID3899

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche (faricimab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEMDA: Black and Ethnic Minority Diabetes Association • Diabetes Research & Wellness Foundation • Diabetes UK • Eyecare Trust • Fight for Sight • Macular Society • National Federation of the Blind of the UK • Network of Sikh Organisations • OBAC (Organisation of Blind African Caribbeans) • Royal National Institute of Blind People • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Optometrists • British and Irish Orthoptic Society • British Geriatrics Society • British Ophthalmic Anaesthesia Society (BOAS) • College of Optometrists • Optical Confederation • Oxford Eye Foundation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Council for the Blind • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • ADVANZ Pharma (dexamethasone) • Alimera Sciences (fluocinolone acetonide) • Allergan (dexamethasone) • Aspen (dexamethasone) • Aspire Pharma (dexamethasone) • Bausch & Lomb (dexamethasone) • Bayer (aflibercept) • Glenmark Pharmaceuticals (dexamethasone) • Hameln pharma (dexamethasone) • Hospira (dexamethasone) • Martindale Pharma (dexamethasone) • Novartis Pharmaceuticals

Provisional stakeholder list for the health technology appraisal of faricimab for treating diabetic macular oedema ID3899

Issue date: April 2021

© National Institute for Health and Care Excellence 2021. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Cambridgeshire and Peterborough CCG • NHS England • NHS Warwickshire North CCG • Welsh Government 	<p>(dexamethasone, ranibizumab)</p> <ul style="list-style-type: none"> • Organon Pharma (bevacizumab) • Panpharma (dexamethasone) • Pfizer (bevacizumab) • Rayner Pharmaceuticals (dexamethasone) • Roche (bevacizumab) • Rosemont Pharmaceuticals (dexamethasone) • Sanofi (afibercept, dexamethasone) • Synchrony Pharma (dexamethasone) • Teva (dexamethasone) • Thame Laboratories (dexamethasone) • Thea Pharmaceuticals (dexamethasone) • Wockhardt (dexamethasone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Eyes and Vision Group • Eye Hope • Genomics England • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.